Dr. Julio Gomez – Seco

Pulmonology and Sleep Respiratory Medicine​

Dr. Julio Gomez - Seco​

Contact Info

+971 4 41 44444

Designation: Consultant Pulmonologist and Sleep Respiratory Medicine
Specialty: Pulmonology and Sleep Respiratory Medicine
Languages: English and Spanish

Core Competencies

  • Asthma, exercise induced asthma, asthma of difficult control, eosinophilic bronchitis, Chronic Obstructive Pulmonary Disease (COPD: emphysema, chronic bronchitis)
  • Infectious respiratory diseases: upper and lower respiratory infections, COVID-19 (front line worker), tuberculosis, pneumonia, empyema , acute bronchitis
  • Post-COVID assessment
  • Diagnosis and staging lung cancer
  • Venous thromboembolism (VTE), pulmonary hypertension
  • Sleep respiratory disorders: obstructive and central sleep apnea, polysomnography and PAP – titration, CPAP/BiPA
  • Multidisciplinary coordinator for other sleep disorders (integrated by pulmonology, neurology, psychiatry, ENT, maxillofacial – dental, others)
  • Acute and chronic respiratory failure, hypoventilation, chronic oxygen therapy, CP AP/BIPAP
  • Bronchiectasis and cystic fibrosis in adults, sweat test, nebulized antibiotic therapy, chest drainage physiotherapy
  • Comprehensive Pulmonary Function Test Unit: Bronchial challenge test with Mannitol, spirometry, bronchodilator test, diffusion lung capacity, lung volumes (plethysmography, dilution), oscillometry, PIM/PEM, P0.1, others
  • Respiratory exercise assessment: 6-minute walking test, cardiopulmonary exercise test
  • Bronchoscopy: bronchoalveolar lavage, transbronchial needle aspiration, bronchial and transbronchial biopsies, EBUS (ultrasound guided bronchoscopy)
  • Pleural diseases: pleural drainage, thoracentesis, pleural biopsy, trained in medical thoracoscopy
  • Respiratory outpatients and inpatients

Brief Profile

  • Dr. Julio Gomez-Seco has 17 years experience in the field of pulmonology and specializes in treating a wide variety of respiratory conditions.
  • During his career, he has been elected as a member of the European Respiratory Society (ERS), the Spanish Respiratory Society (SEPAR), the Saudi Thoracic Society and the Respiratory Society of Madrid (NeumoMadrid). 
  • He worked as a Consultant Pulmonologist in Spain for 12 years where he combined his clinical practice with academic practice as Adjunct Clinical Assistant Professor in the Department of Medicine in College of Medicine of the Autonoma University of Madrid, and Health Research Institute IIS-FJD (Madrid) and as a researcher with the Health Research Institute IIS-FJD in Madrid. 
  • Dr. Gomez-Seco came to Dubai in 2015, after working in the Respiratory Unit for the Security Forces Hospital in Saudi Arabia. Once in Dubai, he took on the role of Head of Pulmonary Department at NMC Royal DIP Hospital before joining King’s College Hospital London in Dubai as Lead Consultant Pulmonology and Sleep Respiratory disorders since 2018.

Qualifications

  • University Degree in Medicine and Surgery, 1991–1997, Autonoma University of Madrid (Madrid, Spain)
  • University Degree, Doctor – Specialist Respiratory Medicine, 1999–2003, Spanish Ministry of Health (Madrid, Spain)
  • Completion of PhD courses and Research proficiency, 1999–2002, Autonoma University of Madrid (Madrid, Spain)
  • Master’s degree in Advances in Diagnosis/Treatment of Airway Diseases, 2016–2017, University of Murcia (Murcia, Spain)
  • University Degree in Medicine and Surgery, 1991–1997, Autonoma University of Madrid (Madrid, Spain)
  • Adjunct Clinical Assistant Professor: Department of Medicine, College of Medicine, Autonoma University of Madrid, Spain (EU), 2012 – 2015
  • Adjunct Clinical Assistant Professor: Department of Medicine, College of Medicine, University of Sharjah, United Arab Emirates, January 2020

Medical Societies and memberships

  • University Degree in Medicine and Surgery, 1991–1997, Autonoma University of Madrid (Madrid, Spain) 
  • Since June 1999, Spanish Respiratory Society (SEPAR)
  • Since June 1999, Respiratory Society of Madrid (NeumoMadrid)
  • From 2008-2015, Health Research Institute IIS – FJD (Madrid)
  • Since February 2015, European Respiratory Society (ERS)

Research and publications

  • Predictive factors of bad pulmonary outcome at three years in a single center cohort of patients withconnective tissue disease-associated interstitial lung disease. Franco C, Carballosa P, Sanchez O, FamiliarV, Rodriguez M.J, Martinez MJ, Martinez R, Gómez-Seco J, Herrero G, Romero F. Ann RheumDis2015;74(Suppl2): 1126
  • Effect of repeated infusions of Rituximab in patients with Primary Sjögren ́s Syndrome. Pérez M.,Recuero S., Romero F. I., Serrano C., Rodríguez M.J., Gómez-Seco J., Presa T., Godo J., Herrero G.,Sánchez, O. Arthritis & Rheumatism 2012, 64: Suppl. 10, 749s-750s
  • Efficacy of Rituximab in patients with connective tissue disease-associated interstitial lung disease:Preliminary results in safety and clinical response. Gómez-Seco J., Rodríguez M.J., Romero F.I., RecueroS., Presa T., Sánchez, O., Villar-Álvarez F., Fernández I. European Respiratory Journal 2012; 40: Suppl. 56,309s.
  • Metabolomic fingerprinting in the identification of biomarkers in COPD patients. Villar-F., García-A.,Ferrarini A., Gómez-Seco J., Rodríguez M., Ruiz-Cabello J., Barbas C., Peces G. European RespiratoryJournal 2012; 40: Suppl. 56, 258s.
  • Vascular dysfunction and systemic inflammation in patients with COPD. Villar F., Peces G., Gómez-Seco J., Rodriguez MJ., Gallegos B., Rguez M., Martín A., Fdez I. European Respiratory Journal 2011; 38:Suppl. 55, 120s.
  • Paragonimiasis Pulmonar. Gómez-Seco, J, Rodríguez M,Rodríguez MJ, Fernández, P, Presa, T , FortesJ. Arch Bronconeumol. 2011;47(12):610–612
  • Antracofibrosis o antracoestenosis. Gómez-SecoJ, PérezI, Guerrero J, Sáez F, Fernández I , RodríguezMJ. Arch Bronconeumol.2012; 48 (4): 133-136
  • Hypersensitivity pneumonitis caused by esparto dust in a young plaster worker. Flandes, Heili, JulioGómez Seco, Sabillón, Fernández, Ortega. Respiration 2004; 71:421-423
  • Reliability of Venturi Devices in Oxygen Therapy. J. Gómez Seco, MJ. Rodríguez, S. Heili, O. Sabillón, I.Fernández, A. Ortega, N. González Mangado. Arch Bronconeumol 2003; 39(6): 256-60
  • Efficacy of Hayek oscillator in bronchiectasis. S. Heili, R. Cabarcos, C. Aguado, M.A. Bodoque, M.Martínez, S. López, J. Gómez Seco, O. Sabillón, I. Fernández, G. Peces-Barba. Revista de PatologíaRespiratoria 2002; 5 (2): 55-59
  • Small airways functional study: BOOP, description of a case. Heili; Julio GómezSeco; Sabillón;Fernández; Ortega; González Mangado; Peces-Barba; Rodríguez Nieto Revista de Patología Respiratoria2003 ;6(2):72-74
  • Semi invasive Aspergillosis coexisting with Allergic Bronchopulmonary Aspergillosis. S. Heili, J. GómezSeco, O.Sabillón, I. Fernández, A. Ortega, G. Peces-Barba, R. Melchor. Revista de Patología Respiratoria2003; 6(4): 180-182

Chapters accepted for publication

  • Capacidad de Difusión. González-Mangado,MJ Rodriguez, Julio Gómez-Seco. NeumoMadridMonographies: Pulmonary Function Tests. Vol XVIII (2011): 45-58
  • E-Newsletter EPID-Futuro, newsletter XII/2015, March 2015. Bibliography reference: “Associationbetween occupational dust exposure and prognosis of idiopatic pulmonary fibrosis: A Korean nationalsurvey. Chest 2014, October 2 (epub ahead of print)”
  • E-Newsletter EPID-Futuro, newsletter III/2012, October 2012. Bibliography reference: “Evidence–based recommendations in IPF: a year is a long time in interstitial lung disease. Müller-Quernheim J etal. Am J Respir Crit Care Med 2012; 186: 5-7”
  • “Smoking and occult psychiatric illness” F. Villar-Álvarez, Julio Gómez-Seco, G. Peces-Barba. Revista dePatología Respiratoria, 2011; 14 (2): 57-60
  • “Chapter 2, Physiopathological issues that generate exercise limitation”. Julio Gómez Seco; Mª JesúsRodríguez Nieto. AQUILES Program: SEPAR Course of Exercise test in Pulmonology. FMC-SEPAR. Ed2010
  • “Chapter 8: Preoperatory risk assessment”. Mª Jesús Rodríguez Nieto; Julio Gómez Seco. AQUILESProgram: SEPAR Course of Exercise test in Pulmonology. FMC-SEPAR. Ed 2010
  • “Chapter 2, Physio pathological issues that generate exercise limitation. Julio Gómez Seco; Mª JesúsRodríguez Nieto. AQUILES Program: SEPAR Course of Exercise test in Pulmonology. FMC-SEPAR. Ed2011
  • “Chapter 8: Preoperatory risk assessment” Mª Jesús Rodríguez Nieto; Julio Gómez Seco. AQUILESProgram: SEPAR Course of Exercise test in Pulmonology. FMC-SEPAR. Ed 2011
  • Co-Author of the Pharmaco-Therapeutic Guidelines in Balearic Islands (IBSALUT). CME ProgramINFORMED 2006-200. Workgroup “Update in Asthma treatment”
  • Co-Author of the Pharmaco-Therapeutic Guidelines in Balearic Islands (IBSALUT). CME ProgramINFORMED 2006-200. Workgroup “Update in COPD treatment”

Research projects

  • Collaborator-Researcher of MulticentrePhase III CIVITAS study, 2015-2016: “Randomized, StudyInvestigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson ́s Disease Patients withMotor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control”.Duration: 1 year
  • Collaborator-Researcher of Multicentre Project (VARCO project), 2013-2015: “Reference Values formaximal Oxygen Uptake, Lactic threshold, Ventilatory reserve and Cardiac reserve in a Spanish Cohort,European descendants (VARCO study)”. Duration: 2 years (2013-2015). Number of Researchers: 14.Sponsor: SEPAR-PII Rehabilitation and respiratory diseases (Integrated Research Program)
  • Collaborator-Researcher REVASC Project, 2011-ongoing. CAIBER: “Randomized, double-blind andPlacebo-controlledClinical study for the evaluation of the endothelial effect of Roflumilast in COPDpatients”. Protocol code number: CIB-ROF-2011-01. Sponsor: CIBERES
  • Collaborator-Researcher ASSESS study, 2011-2013: “Observational Study on Characterization of 24hSymptoms in Chronic Obstructive Pulmonary Disease Patients (ASSESS study)”. Protocol code number:M/34273/42. Sponsor: Almirall S.A. Publication (reference): Miravitlles M, Worth H, Soler JJ, Price D, DeBenedetto F, Roche N, Godtfredsen NS, van der Molen T, Löfdahl C-G, Padullés L, Ribera A. Respir Res2014
  • Collaborator-Researcher 2012: “Identification of new pathogenic pathways induced by arginaseactivation in stable, exacerbated and bronchiectasis-associated COPD patients” Sponsor: first awardBoehringer-Pfizer/XVII Neumomadrid Congress

Congress presentations

  • “Predictive factors of bad pulmonary outcome at three years in a single center cohort of patients withconnective tissue disease-associated interstitial lung disease”. Franco C, Carballosa P,Sanchez PernauteO, Familiar V, Rodriguez Nieto M.J, Gomez-Seco J, Herrero Beaumont G, Romero Bueno F. The EuropeanLeague against Rheumatism (EULAR 2015). Rome (Italy). June 2015
  • “Effect of repeated infusions of Rituximab in patients with Primary Sjögren ́s Syndrome”. Pérez M.,Recuero S., Romero F. I., Serrano C., Rodríguez M.J., Gómez-Seco J., Presa T., Godo J., Herrero-BeaumontG., Sánchez-Pernaute, O. American College of Rheumatology ACR. Washington DC (USA). November 2012
  • “Efficacy of Rituximab in patients with connective tissue disease-associated interstitial lung disease:Preliminary results in safety and clinical response”. Gómez-Seco J., Rodríguez-Nieto M.J., Romero-BuenoF.I., Recuero S., Presa-T., Sánchez-Pernaute, O., Villar F., Fernández I. European Respiratory SocietyAnnual Congress (ERS 2012). Vienna-Austria. September 2012
  • “Metabolomic fingerprinting in the identification of biomarkers in COPD patients”. Villar F., García A.,Ferrarini A., Gómez-Seco J., Barbas-Arribas C., Peces-Barba G. European Respiratory Society AnnualCongress (ERS 2012). Vienna-Austria. September 2012
  • “Effect of repeated infusions of Rituximab in patients with Primary Sjögren ́s Syndrome”. Pérez M.,Romero F. I., Recuero S., Rodríguez-Nieto M.J., Gómez-Seco J., Serrano C., Presa T., Herrero-BeaumontG., Sánchez-Pernaute, O. The European League against Rheumatism (EULAR 2012). Berlin (Germany), June 2012
  • “Characterization of our cohort with connective tissue disease-associated interstitial lung disease”.Romero F, Gómez-Seco J., Rodríguez-Nieto MJ, Presa T., Mahillo I., Herrero-Beaumont G. 5th AsianCongress on Autoimmunity (ACA 2011). Singapore. November 2011
  • “Vascular dysfunction and systemic inflammation in patients with COPD”. Villar-Álvarez F., Peces-Barba G., Gómez-Seco J., Rodriguez-Nieto MJ., Gallegos B., Rguez M., Martín A., Fdez-Ormaechea I.European Respiratory Society Annual Congress (ERS 2011), Amsterdam-Netherlands. September 2011
  • “Impact of different molecular weight inert gases on lung carbon monoxide diffusion capacity”. Heili S,Gómez-Seco J, Rodríguez-Nieto MJ, Peces-Barba G, Gonzalez Mangado N. Proceedings of the AmericanThoracic Society.Volume2 Abstracts Issue 2005: A777 ATS International Conference, S. Diego, USA, Mayo 2005
  • “Description of our seriewith connective tissue disease-associated interstitial lung disease”. Gómez-Seco J., Rodriguez-Nieto M.J., Romero F.I., Presa T., Mahillo I., Sánchez-Pernaute O., Troncoso F.,González-Mangado N. 45th SEPAR Congress. Madrid, June 2012
  • “Functional Description of our serie with connective tissue disease-associated interstitial lungdisease”. Gómez-Seco J., Rodriguez-Nieto M.J., Romero F.I., Presa T., Sánchez-Pernaute O., Mahillo I.,Villar-Álvarez F., Fdez-Ormaechea I. 45th SEPAR Congress. Madrid, June 2012
  • “Bronchoscopic Description of our serie with connective tissue disease-associated interstitial lungdisease”. Gómez-Seco J., Rodriguez-Nieto M.J., Romero F.I., Presa T., Sánchez-Pernaute O., Mahillo I.,Fdez I., Flandes J. 45th SEPAR Congress. Madrid, June 2012
  • “Rituximab: Clinical response to in patients with CTD-ILD”. Rodriguez-Nieto M.J., Gómez-Seco J.,Romero F.I., Presa T., Gallegos B., Sánchez-Pernaute O. 45th SEPAR Congress. Madrid, June 2012
  • “First serie of Anthracostenosisin Spain”. Gómez-Seco J., Pérez-Boal I., Guerrero-Glez J., Sáez-Noguero F., Rodriguez-Nieto M.J., Fdez-Navamuel I. 45th SEPAR Congress. Madrid, June 2012
  • “Study of the cardiovascular risk in COPD. Phenotypic characterization”. Villar-Álvarez F., Peces-BarbaG., Gómez-Seco J., Fdez-Ormaechea I., Martin A, Saavedra Z., Cabrejos I., Pelicano S., Mahillo I.. 45thSEPAR Congress. Madrid, June 2012
  • “Clinic and polysomnographic characterization in Restless Legs Syndrome in our MultidisciplinaryUnit”Gallegos B., Martínez R., Troncoso F., Gómez T., Rodríguez M., Gómez-Seco J., González-MangadoN. 45th SEPAR Congress. Madrid, June 2012
  • “Clinical features of patients with bronchiectasis in a Pulmonology Outpatient Unit”. Álvarez-SuárezL.; Martínez-Carranza R.A.; Saavedra-Moreno Z.E.; Cabrejos-Salinas I.R.; Pérez-Warnisher M.T.; Gómez-Seco J.; Melchor-Iñiguez R. XIX NeumoMadrid Congress. Madrid, April 2014
  • “Anthracostenosis, an entity never seen before in our Country” Gómez-Seco J., Pérez-BoalI.,Guerrero-Glez J., Sáez-Noguero F., Rodriguez-Nieto M.J., Fdez-Navamuel I. Fdez-Ormaechea I. XVIINeumoMadrid Congress. Madrid, April 2012
  • “CTD-ILD: description of our serie”. Rodriguez-Nieto M.J., Gómez-Seco J., Romero F.I., Presa T.,Sánchez-Pernaute O., Mahillo I., Troncoso F., González-Mangado N. XVII NeumoMadrid Congress.Madrid, April 2012
  • “CTD-ILD serie: PFT ́s data”. Gómez-Seco J., Rodriguez-Nieto M.J., Fdez-Ormaechea I., Romero F.I.,Presa T., Sánchez-Pernaute O., Villar-Álvarez F., González-Mangado N. XVII NeumoMadrid Congress.Madrid, April 2012
  • “CTD-ILD: Bonchoscopic description of our serie. Gómez-Seco J., Rodriguez-Nieto M.J., Presa T.,Romero F.I., Sánchez-Pernaute O., Rodríguez-Guzmán M., Flandes-Aldeiturriaga J., Fdez-Navamuel I.XVII NeumoMadrid Congress. Madrid, April 2012
  • “Results of Rituximab treatment in CTD-ILD” Rodriguez-Nieto M.J., Gómez-Seco J., Romero F.I.,Serrano C., GallegosB., Presa T., Mahillo I., Sánchez-Pernaute O. XVII NeumoMadrid Congress. Madrid, April 2012
  • “Influence of Smoking in prediction of cardiovascular risk in respiratory diseases using blood andUrine analysis and arterial Tonometry”. Villar-Álvarez F., Peces-Barba G., Gómez-Seco J., Rodriguez-Nieto MJ., Gallegos B., Rguez-GuzmanM., Saavedra Z., Cabrejos I. XVII NeumoMadrid Congress. Madrid, April 2012
  • “Characterization of Pulmonary High Blood pressure in OSAS patients” 44th SEPAR Congress. Oviedo, June 2011
  • “Measurement of inflammation and cardiovascular risk in COPD”44th SEPAR Congress, Oviedo, June 2011
  • “Systemic inflammation and vascular dysfunction in COPD. Villar-Álvarez F., Peces-Barba G., Gómez-Seco J., Rodriguez-Nieto MJ., Gallegos B., PelícanoS.XVI NeumoMadrid Congress. Madrid,April 2011
  • “Clinical characteristics in patients with OSAS-PH” Rguez-Guzman M., Gallegos B., Martín A.,Troncoso F., Rodriguez-Nieto MJ.,Gómez-Seco J., Villar-Álvarez F., González-Mangado N. XVINeumoMadrid Congress, Madrid, April 2011
  • “Functional evaluation in Combined Pulmonary Fibrosis and Emphysema Syndrome” Martín A.,Rguez-Guzman M., Gallegos B., Rodriguez-Nieto MJ., Gómez-Seco J., Villar-Álvarez F. XVI Neumo Madrid Congress. Madrid, April 2011
  • “Tracheobronchial Histoplasmosis”. J. Gómez Seco, S. Heili, I. Fernández, O. Sabillón, A. Ortega, R.Melchor. VIII Neumo Madrid Congress. Madrid, April 2003
  • “ARDS secondary to hepatic Chemoembolization” J. Gómez Seco, S. Heili, I. Fernández, O. Sabillón, A.Ortega, R. Melchor. VIII NeumoMadrid Congress. Madrid, April 2003
  • “Atypical presentation of a Legionella pneumonia like cholecystitis” A. Ortega, J. Gómez Seco, S. Heili,O. Sabillón, I. Fernández, MJ. Rodríguez Nieto. VIII Neumo Madrid Congress. Madrid, April 2003
  • “Pulmonary involvement of a Skin T-Lymphoma” I. Fernández, J. Gómez Seco, S. Heili, O. Sabillón, A.Ortega, MJ. Rodríguez Nieto. VIII NeumoMadrid Congress. Madrid, April 2003
  • “Breast metastasis of a SCLC”. I. Fernández, J. Gómez Seco, S. Heili, O. Sabillón, A. Ortega, MJ.Rodríguez NietoVIII NeumoMadrid Congress. Madrid, April 2003
  • “Allergic Bronchopulmonary coexisting with Aspergillosis Semi invasive Aspergillosis” S. Heili, J.Gómez Seco, I. Fernández, O. Sabillón, A. Ortega, R. Melchor. VIII NeumoMadrid Congress. Madrid, April 2003
  • “Hypersensitivity pneumonitis caused by esparto dust in a young plasterworker” S.Heili, J. GómezSeco, I. Fernández, O. Sabillón, A. Ortega, R. Melchor. VIII NeumoMadrid Congress. Madrid, April 2003
  • “Utility of BAL for diagnosis of Lymphoproliferative diseases” O. Sabillón, J. Gómez Seco, S. Heili, I.Fernández, A. Ortega, R. Melchor. VIII NeumoMadrid Congress. Madrid, April 2003
  • “Oxygen therapy devises: Venturi Oxygen Systems”. J. Gómez Seco, MJ. Rodríguez Nieto, S. Heili, O.Sabillón, I. Fernández, S. López, N. González Mangado. 35th SEPAR Congress. Gran Canaria, June 2002
  • “Comparison of pneumonic vs. non-pneumonic acute exacerbation of COPD” S. López, O. Sabillón, I.Ormaechea, J. Gómez Seco, R. Melchor. 35th SEPAR Congress, Gran Canaria, June 2002
  • “Gas exchange alteration in COPD patients admitted with pneumonia” S. López, O. Sabillón, I.Ormaechea, J. Gómez Seco, R. Melchor. VII NeumoMadrid Congress, Madrid, April 2002
  • “Venturi oxygen systems: Analysis” J. Gómez Seco, S. Heili, O. Sabillón, I. Fernández, MJ. RodríguezNieto. VII NeumoMadrid Congress. Madrid, April 2002
  • “Precoital hemoptysis” J. Gómez Seco, S. Heili, O. Sabillón, I. Fernández, J. Flandes. VII NeumoMadridCongress. Madrid, April 2002
  • “Pulmonary embolism: Diagnostic Concordance–discordance” J. Gómez Seco, S. Heili, O. Sabillón, I.Fernández, R. Melchor. VII NeumoMadrid Congress. Madrid, April 2002
  • “Herpes Irisand Mycoplasmapneumoniae”. I. Fernández, J. Gómez Seco, S. Heili, O. Sabillón, R.Melchor VII NeumoMadrid Congress. Madrid, April 2002
  • “Respiratory physiotherapy and Hayek Oscillator”. S. Heili, R. Cabarcos, J. Gómez Seco, O. Sabillón, I.Fernández, G. Peces-Barba. VII NeumoMadrid Congress. Madrid, April 2002
  • “Cystic lesion with hydro-aerial level and water lily sign” S. Heili, J. Gómez Seco, O. Sabillón, I.Fernández, R. Melchor. VII NeumoMadrid Congress. Madrid, April 2002
  • “Drainage of phlegm in patients with Bronchiectasis: Hayek oscillator ́s efficacy” Heili S., Cabarcos R,Bodoque MA, Martínez Díaz M, López S, J. Gómez Seco, Fernandez Ormaechea I. VII Neumo Madrid Congress, Madrid, April 2002

Nationality: Spain 

Number of Years of Experience: 17 years